Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The <keyword id="22407175" type="General" weightage="100" keywordseo="U-WIN" source="keywords">U-WIN</keyword> portal, a replication of the <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">Covid-19</keyword> vaccine management system Co-WIN, is set for a pan-India launch likely by the end of August, aiming to maintain an electronic registry of routine immunisations, official sources said. Currently, U-WIN is in pilot mode across all states and Union Territories, except for West Bengal, which is yet to start uploading data, the sources told PTI, adding that it is still under consideration in the state. The U-WIN platform captures every <keyword id="19933690" type="General" weightage="20" keywordseo="vaccination" source="keywords">vaccination</keyword> event for pregnant women and children under the Universal Immunization Programme (UIP). Minister of Finance <keyword id="19916618" type="General" weightage="20" keywordseo="nirmala-sitharaman" source="keywords">Nirmala Sitharaman</keyword> had announced in the interim Budget for 2024-2025 that U-WIN, along with intensified efforts under Mission Indradhanush, will be rolled out nationwide for managing <keyword id="21423640" type="General" weightage="20" keywordseo="immunisation" source="keywords">immunisation</keyword>. "The U-WIN will ensure timely administration of vaccine doses by digitally recording every vaccination event under the Universal Immunisation Programme among all pregnant women and children aged 0-5 years," an official told PTI. "The portal will target 2.9 crore pregnant women and 2.6 crore infants (0-1 years) annually by providing 11 vaccines against 12 vaccine preventable diseases -- diphtheria, measles, rubella, and tetanus through more than 1.2 crore vaccination sessions across the country," the official added. The platform generates a uniform QR-based, digitally verifiable e-vaccination certificate, similar to Covid vaccination certificate, which can be accessed anytime by the citizens through a single click. Vaccination records under UIP are being maintained manually as of now. So this will do away with the hassle of keeping a physical record, the officials explained. It will enable the digitisation of session planning, and updating vaccination status on a real-time basis, they added. "Also, there is no mechanism of individual tracking. There is also lack of awareness among beneficiaries about session location and date especially in urban areas and iniquity in immunisation coverage in states and UTs," another official said. "Besides, another major issue is that immunisation at private health facilities is not recorded," the official added. The U-WIN is going to be the single source of information for immunisation services which will record pregnancy details and outcome, newborn registration and immunisation at birth. It will update vaccination status, and delivery outcome, among others, on real time, the official said. As of July 9, 2024, the pilot has registered 5.33 crore beneficiaries on U-WIN. Over 83.55 lakh vaccination sessions have been digitally conducted, and 18.15 crore vaccine doses have been recorded. The platform aims to reduce zero-dose and left-out children through a name-based tracking mechanism and empower citizens with anytime, anywhere access to vaccination services, particularly benefiting migratory populations, the official said. "The U-WIN portal is likely to be launched pan <keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> in August end," the official stated. Citizens can self-register for vaccinations via the U-WIN web portal or its Android mobile application, select preferred vaccination centres, and schedule appointments. Automated SMS alerts inform citizens about registration confirmations, administered doses, and upcoming dose reminders, ensuring timely and age-appropriate vaccinations. It also facilitates the creation of Ayushman Bharat Health Account (ABHA) IDs for comprehensive health record maintenance. The U-WIN also supports the frontline workers to digitally record all vaccination events for children and pregnant women for complete, accurate and easy record maintenance, the official said.

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

The pharmaceutical giant <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>'s <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British Newspaper 'The Telegraph'. AstraZeneca has announced that the <keyword id="19959412" type="General" weightage="20" keywordseo="vaccine" source="keywords">vaccine</keyword> was being removed from markets for commercial reasons. It further said that the vaccine was no longer being made or supplied, having been superseded by updated vaccines that fight new variants. The application to withdraw the vaccine was made on March 5 and came into effect on May 7. The vaccine can be no longer used in the European Union following the company's decision to withdraw its "marketing authorisation." Similar applications will be submitted in the UK and other nations in the coming months that have given a go-ahead to the vaccine, known as Vaxzevria. In recent months, Vaxzevria has come under scrutiny over a very rare side effect, which causes blood clots and low blood platelet counts. In court documents, AstraZeneca in the High Court in February admitted that the vaccine "can, in very rare cases, cause <keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>". TTS which stands for <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> has been associated with at least 81 deaths in the UK and hundreds of serious injuries. More than 50 alleged victims and grieving relatives have filed a lawsuit against AstraZeneca in a High Court case. AstraZeneca has insisted that the decision to withdraw the vaccine is not related to the case or admission that it can cause TTS and termed the timing a pure coincidence, according to The Telegraph report. "We are incredibly proud of the role Vaxzevria played in ending the global pandemic. According to independent estimates, over 6.5 million lives were saved in the first year of use alone and over three billion doses were supplied globally. Our efforts have been recognised by governments around the world and are widely regarded as being a critical component of ending the global pandemic," The Telegraph quoted AstraZeneca as saying. In a statement, the pharmaceutical giant said, "As multiple, variant Covid-19 vaccines have since been developed, there is a surplus of available updated vaccines", adding that it has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied, The Telegraph reported. It further announced its decision to initiate the withdrawal of the marketing authorisations for Vaxzevria within Europe. The company said, "We will now work with regulators and our partners to align on a clear path forward to conclude this chapter and significant contribution to the Covid-19 pandemic." Last week, AstraZeneca reiterated its commitment to patient safety while emphasising the vaccine's overall safety profile. An AstraZeneca spokesperson had stated, "Our sympathy goes out to anyone who has lost loved ones or reported health problems. Patient safety is our highest priority, and regulatory authorities have clear and stringent standards to ensure the safe use of all medicines, including vaccines." This comes in the wake of a recent admission by AstraZeneca, the pharmaceutical company, that its <keyword id="19896627" type="General" weightage="20" keywordseo="covid" source="keywords">Covid</keyword> vaccine Covishield and Vaxzevria "can, in very rare cases, cause Thrombosis Thrombocytopenia Syndrome (TTS)." Despite these rare occurrences, the pharmaceutical company maintained that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy. Regulatory agencies worldwide continue to assert that the benefits of vaccination outweigh the risks of such extremely rare side effects. SEE ALSO:<a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank"></a> <a href="https://www.businessinsider.in/stock-market/webstories/aadhar-housing-finance-ipo-price-band-to-risk-factors-all-you-need-to-know/slidelist/109919298.cms" target="_blank">Aadhar Housing Finance IPO – Price band to risk factors, all you need to know</a><a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank"></a> <a href="https://www.businessinsider.in/business/auto/webstories/top-selling-cars-in-india-in-april-2024-tata-punch-continues-to-dominate/slidelist/109909744.cms" target="_blank">Top-selling cars in India in April 2024 – Tata Punch continues to dominate</a><a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/worldwide-tablet-shipments-grow-in-q1-2024-after-two-years-of-decline/articleshow/109876390.cms" target="_blank">Worldwide tablet shipments grow in Q1 2024 after two years of decline</a>

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

The Indian Council of Medical Research Director General Dr Rajiv Bahl on Monday criticised a recently published study on the long-term safety analysis of the <keyword id="9485939" type="General" weightage="100" keywordseo="covaxin" source="Orion">Covaxin</keyword> in adults and adolescents for its poor methodology and design, and clarified the article misleadingly and erroneously "acknowledges" <keyword id="19918794" type="General" weightage="20" keywordseo="ICMR" source="keywords">ICMR</keyword>. Dr Bahl said the study had no control arm of unvaccinated individuals for comparing the rates of events between the vaccinated and unvaccinated groups. Hence, the reported events in the study cannot be linked or attributed to COVID-19 vaccination. He added that the ICMR is not associated with the study and has not provided any financial or technical support for the research. The ICMR DG has written a letter to the authors of the paper and Editor of the journal to immediately remove the acknowledgement to ICMR and publish an erratum. A research paper, titled 'Long-Term Safety Analysis of the BBVl52 <keyword id="21730391" type="General" weightage="20" keywordseo="coronavirus-vaccine" source="keywords">Coronavirus Vaccine</keyword> in Adolescents and Adults: Findings from a l-Year Prospective Study in North India' stated that nearly one-third of the 926 participants in the study who received Bharat Biotech's anti-Covid vaccine Covaxin reported 'adverse events of special interest,' or AESI. Dr Bahl said that ICMR was acknowledged for research support without any prior approval of or intimation to ICMR, which is inappropriate and unacceptable. He stated that ICMR cannot be associated with this poorly designed study which purports to present a "safety analysis" of Covaxin due to several critical flaws. He said the study does not even provide background rates of observed events in the population, making it impossible to assess the change in incidence of observed events in the post-vaccination period. Baseline information of study participants is missing. The study tool used is inconsistent with 'Adverse Events of Special Interest (AESI)' as defined in the reference provided in the paper for AESI. The method of data collection has a high risk of bias, he said. Study participants were contacted telephonically one year after vaccination and their responses were recorded without any confirmation with clinical records or by physician examination, he pointed out. Dr Bahl also noted that similar acknowledgements to ICMR have been made in previous papers without permission, raising concerns about the authors' practices. "The authors have been urged to immediately rectify the acknowledgment to ICMR and publish an erratum. Additionally, they are asked to address the methodological concerns raised. Failure to do so may prompt ICMR to consider legal and administrative action," he said. The Editor has been asked to retract the paper which implicitly makes conclusions on <keyword id="21495684" type="General" weightage="20" keywordseo="vaccine-safety" source="keywords">vaccine safety</keyword> which are not supported by evidence. The study, conducted by researchers from the Banaras Hindu University from January 2022 to August 2023, stated that nearly 50 per cent of 926 study participants in the study complained of infections during the follow-up period, predominated by viral upper respiratory tract infections. Serious AESI, which included stroke and Guillain-Barre syndrome, were reported in one per cent of individuals, the study, which looked at long-term safety of the BBV152 (Covaxin) vaccine in adolescents and adults, claimed. The study involved 635 adolescents and 291 adults, who received the BBV152 vaccine.

BHU study on Covaxin side effects poorly designed, critically flawed: ICMR Director General

Medical expert Dr Rajeev Jayadevan said that <keyword id="21480687" type="General" weightage="20" keywordseo="Thrombosis-Thrombocytopenia-Syndrome" source="keywords">Thrombosis Thrombocytopenia Syndrome</keyword> (<keyword id="20218859" type="General" weightage="20" keywordseo="TTS" source="keywords">TTS</keyword>) refers to the <keyword id="21480686" type="General" weightage="20" keywordseo="clot-in-blood-vessels" source="keywords">clot in blood vessels</keyword>, and it occurs in very rare cases, following the use of certain types of <keyword id="19953288" type="General" weightage="20" keywordseo="vaccines" source="keywords">vaccines</keyword>. Acknowledging that the <keyword id="20250806" type="General" weightage="20" keywordseo="COVID-vaccines" source="keywords">Covid vaccines</keyword> have helped in preventing numerous deaths, Jayadevan, who is the Co-Chairman of National Indian Medical Association (IMA) Covid Task Force in Kerala, stated that reports of such cases have also been highlighted in many reports. "TTS is thrombosis with thrombocytopenia syndrome, which is basically clot in blood vessels of the brain or elsewhere, along with a low platelet count. It is known to occur in very rare instances following certain types of vaccines and also from other causes. According to the WHO, adenovirus vector vaccines in particular have been rarely associated with this condition," he told ANI. "Although COVID vaccines have prevented numerous deaths, reports of these extremely rare but potentially serious immune mediated events have also been published in reputed journals," Dr Jayadevan added. This comes in the wake of a recent admission by <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword>, the pharmaceutical company, that its Covid vaccine Covishield and Vaxzevria "can, in very rare cases, cause TTS." According to several UK media reports, AstraZeneca has made the admission in court documents in connection with a case that alleges that the vaccine, developed with the University of Oxford, caused death and serious injury in dozens of cases. The Serum Institute of India produced COVID-19 vaccine named Covishield but not using mRNA platform. It has been prepared using the viral vector platform. In the vaccine, a chimpanzee adenovirus - ChAdOx1 - has been modified to enable it to carry the COVID-19 spike protein into the cells of humans. This cold virus is basically incapable of infecting the receiver, but can very well teach the immune system to prepare a mechanism against such viruses. The same technology was used to prepare vaccines for viruses like Ebola. Amid reports about clot in blood vessels in the UK media, the Serum Institute of India did not respond to the query. Notably in 2023, the World Health Organisation (WHO) said in its report that TTS emerged as a new adverse event following immunisation in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson &amp; Johnson (J&amp;J) Janssen COVID-19 Ad26.COV2-S vaccines. "TTS is a serious and life-threatening adverse event. WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination and help healthcare providers in the assessment and management of potential TTS cases," the 2023 statement by WHO read. However, Union Health Minister Mansukh Mandaviya in March 2024 at 'Dialogues - Navigating India's health sector' said that ICMR has done a detailed study which shows that COVID-19 vaccine is not responsible for heart attacks, and an individual's lifestyle and factors such as binge drinking could be among underlying causes. Mandaviya said, "If someone has a stroke today, they think it is because of the Covid vaccine. ICMR has done a detailed study that the (Covid) vaccine is not responsible for heart attacks." (ANI)

TTS: Clot in blood vessels occurs in rare cases with certain vaccines, says medical expert amid reports over AstraZeneca

<keyword id="19895045" type="General" weightage="20" keywordseo="Singapore" source="keywords">Singapore</keyword> is seeing a new <keyword id="21710881" type="General" weightage="20" keywordseo="Covid-19-wave" source="keywords">COVID-19 wave</keyword> as the authorities recorded more than 25,900 cases from May 5 to 11 even as <keyword id="19962428" type="General" weightage="20" keywordseo="Health-Minister" source="keywords">Health Minister</keyword> <keyword id="19895083" type="General" weightage="20" keywordseo="Ong-Ye-Kung" source="keywords">Ong Ye Kung</keyword> on Saturday advised the wearing of masks again. "We are at the beginning part of the wave where it is steadily rising," said Ong. "So, I would say the wave should peak in the next two to four weeks, which means between mid- and end of June," The Straits Times newspaper quoted the minister as saying. The Ministry of Health (MOH) said the estimated number of COVID-19 cases in the week of May 5 to 11 rose to 25,900 cases, compared with 13,700 cases in the previous week. The average daily COVID-19 hospitalisations rose to about 250 from 181 the week before. The average daily intensive care unit (ICU) cases remained low at three cases, compared with two cases in the previous week. The MOH said that to protect hospital bed capacity, public hospitals have been asked to reduce their non-urgent elective surgery cases and move suitable patients to transitional care facilities or back home through Mobile Inpatient Care@Home, an alternative inpatient care delivery model that offers clinically suitable patients the option of being hospitalised in their own homes instead of a hospital ward. Ong urged those who are at greatest risk of severe disease, including individuals aged 60 years and above, medically vulnerable individuals and residents of aged care facilities, to receive an additional dose of the COVID-19 vaccine if they have not done so in the last 12 months. Ong said that if the number of COVID-19 cases doubles one time, Singapore will have 500 patients in its healthcare system, which is what Singapore can handle. However, if the number of cases doubles a second time, there will be 1,000 patients, and "that will be a considerable burden on the hospital system", he pointed out. "One thousand beds is equivalent to one regional hospital," Ong said. "So, I think the healthcare system has to brace ourselves for what is to come." There are no plans for any form of social restrictions or any other mandatory kind of measures for now, as COVID-19 is treated as an endemic disease in Singapore, he said, adding that imposing additional measures would be a last resort. Ong said that with Singapore being a transport and communications hub, it will be one of the cities to get a wave of COVID-19 earlier than others. "So, COVID-19 is just something that we have to live with. Every year, we should expect one or two waves," he said. Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. Currently, KP.1 and KP.2 account for over two-thirds of cases in Singapore. As of May 3, the World Health Organisation has classified KP.2 as a variant under monitoring. There are currently no indications, globally or locally, that KP.1 and KP.2 are more transmissible or cause more severe disease than other circulating variants, the MOH said. However, members of the public are urged to stay updated with vaccinations to protect themselves against current and emerging virus strains. The MOH said that to date, about 80 per cent of the local population have completed their initial or additional dose, but have not received a dose within the last year. The ministry added that since COVID-19 vaccination started in 2020 to 2021, the vaccines have consistently been proven to be safe and effective in protecting individuals from severe illness. Billions of doses have been administered globally, and safety monitoring internationally has shown that the vaccine is safe, it said. There have also been no long-term safety concerns with COVID-19 vaccination, and adverse effects from vaccines, including the mRNA vaccines, have all been observed to occur shortly after vaccination, the ministry added. SEE ALSO:<a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/motorola-edge-50-fusion-vs-oneplus-nord-ce-4-price-specs-and-features-compared/slidelist/110197390.cms" target="_blank">Motorola Edge 50 Fusion vs OnePlus Nord CE 4 – price, specs and features compared</a><a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/webstories/iqoo-z9x-5g-with-120hz-display-6000mah-launched-starting-at-12999/slidelist/110176453.cms" target="_blank">iQOO Z9x 5G with 120Hz display, 6000mAh launched starting at ₹12,999</a><a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank"></a> <a href="https://www.businessinsider.in/india/news/woman-loses-54-lakh-in-work-from-home-scam-heres-what-it-is-and-how-to-protect-yourself/articleshow/110166963.cms" target="_blank">Woman loses ₹54 lakh in work-from-home scam! Here's what it is and how to protect yourself</a>

Singapore seeing new COVID-19 wave, minister advises wearing of masks

<ul class="summary-list"><li>Starboard Value has taken a $1 billion stake in drugmaker Pfizer.</li><li>The hedge fund, headed by Jeff Smith, has become one of the most feared activist investors.</li></ul>Pharmaceuticals giant Pfizer got a wake up call Sunday evening when one of Wall Street's most feared activist investors revealed a stake in the company.Starboard Value <a target="_blank" class="" href="https://www.businessinsider.com/starboard-activist-significant-stake-in-drugmaker-pfizer-2024-10">informed the drugmaker</a> it had taken a position in the firm valued at $1 billion.An activist's aims, whether that's pushing for breakup, M&amp;A, or cost reductions, vary depending on the target. Starboard's turnaround strategy is not yet clear, but Pfizer's share price and revenues have tumbled from the record highs achieved during the pandemic's heights, and Starboard, led by its 52-year-old cofounder Jeff Smith, has a long history of wielding minority stakes to extract board seats and profits from name-brand companies.Over the past decade, Smith has more than doubled the hedge fund's assets under management to $8.5 billion by taking on targets including Salesforce, Starbucks, and the owner of Olive Garden. In that time Starboard has gained a reputation for making life uncomfortable for — and sometimes jettisoning — executives and directors who resist his overtures for change.Pfizer, with a market cap north of $160 billion, is among the largest companies Starboard's Smith has ever targeted. Still, investors seemed to applaud news of its investments on Monday, sending Pfizer's stock up about 3% in morning trading, adding nearly $5 billion to the company's market cap.Moreover, Starboard has reportedly secured support from <a target="_blank" href="https://www.wsj.com/health/pharma/activist-starboard-value-takes-1-billion-stake-in-pfizer-89591cb6?mod=hp_lead_pos4">former Pfizer executives</a> Ian Read and Frank D'Amelio for its campaign.Starboard has experience across the spectrum but is especially good at instilling discipline at the board level and "improving margins and cutting costs at companies that are bloated," said Ken Squire, the founder and president of 13D Monitor, a research firm specializing in shareholder activism.Starboard declined to comment.<h2 id="44e54273-f674-45fa-9c95-4d5153293525">Who is Jeff Smith?</h2>Investor activism has exploded in recent years. The 147 new campaigns globally in the first half of 2024 is a record, building on the all-time high 252 campaigns reached in 2023, according to a July report from investment bank Lazard.Starboard has become one of the most formidable names in the business, even if Smith hasn't yet reached the name recognition of activist investors like Paul Singer (Elliott Management), Carl Icahn (Icahn Enterprises), and Dan Loeb (Third Point Capital).Smith launched Starboard in 2011, spinning it out of a <a target="_blank" href="https://www.cowen.com/news/ramius-announces-spin-off-of-value-and-opportunity-business/">small unit at Cowen Group</a> along with a couple of partners, including Peter Feld. Early targets included AOL, where Starboard lost a proxy battle but agitated for changes that boosted the company's stock by 250%, and Office Depot, where Starboard won three board seats, according to <a target="_blank" href="https://fortune.com/2014/12/03/starboard-capitals-jeff-smith-activist-investor-darden-restaurants/">a 2014 story in Fortune</a>.Starboard put corporate America on notice with its campaign in 2013 against Darden Restaurants, the owner of Olive Garden and Longhorn Steakhouse, among other dining chains. With less than a 10% stake Smith replaced the entire 12-person board and assumed the role of chairman. By the time Smith stepped down in 2016, Darden <a target="_blank" href="https://www.wsj.com/articles/activists-reap-olive-garden-bounty-1459902161">stock had gained nearly 50%</a> and Starboard had accrued more than $500 million in profits.One of the hedge fund's greatest claims to fame involved its <a target="_blank" class="" href="https://www.wsj.com/articles/activists-reap-olive-garden-bounty-1459902161">improvements to Olive Garden's breadsticks</a>, which Starboard predicted could save the company up to $5 million a year, according to a Wall Street Journal report from 2015.In 2022, Starboard took a <a target="_blank" class="" href="https://www.businessinsider.com/salesforce-profit-margins-starboard-value-turnaround-2023-8">stake in software giant Salesforce</a>, urging the company to cut costs and improve margins. The company's shares have nearly doubled in the two years since.<div type="image" title="Photo of Marc Benioff of Salesforce speaking on stage." height="1333" width="2000" msid="114027436" hostid="261" sizebytes="41886"></div>Starboard's record isn't without blemishes. Its campaign against meat <a target="_blank" href="https://archive.nytimes.com/dealbook.nytimes.com/2015/02/04/a-primer-on-starboard-the-activist-that-pushed-for-a-staples-office-depot-merger/">processor Smithfield Foods</a> in 2013 fizzled. The hedge fund <a target="_blank" href="https://techcrunch.com/2021/09/09/box-wins-proxy-board-battle-with-activist-">lost a proxy battle</a> with software maker Box in 2021. And in 2019 it dropped a bid to have Bristol-Myers Squibb scrap its merger with Celgene after failing to win over <a target="_blank" class="" href="https://www.cnbc.com/2019/03/29/starboard-drops-out-of-celgene-fight-as-proxy-firms-back-bristol-myers-bid.html">two major proxy advisory firms</a>.In total, Starboard has initiated 151 activist campaigns, which have generated an average return of 25%, according to data from 13D Monitor.<h2 id="fc0d4b73-d1a3-4a74-a386-7908a74761a7">Ignore at your peril</h2>More recently, the hedge fund has taken positions in dating app owner Match Group, software company Autodesk, and Starbucks.Squire said Smith has a reputation as intense but intelligent and candid. Starboard "can be friendly, but if they're ignored they can also be feared — and they can get tough."In August, Starbucks replaced its CEO amid a campaign from Starboard and Elliott Management.Given Smith's record of winning corporate concessions — or prying them away by force — Pfizer CEO Albert Bourla may be next in the hot seat. Bourla took over in 2019 and guided the drugmaker through the pandemic, boosting annual revenues to $100 billion in 2022 thanks to sales of its COVID-19 vaccine and the antiviral treatment Paxlovid.But missteps ensued. Pfizer misjudged future demand for COVID remedies, <a target="_blank" href="https://www.wsj.com/health/pharma/pfizer-drug-company-cost-cutting-2da7524d?mod=article_inline">according to a WSJ report</a>, and revenues cratered. It has since undertaken multibillion-dollar cost cutting campaigns.For its next act, Pfizer executives wagered heavily on cancer treatments. It shelled out $43 billion last year to acquire Seagen, a Washington-based biotech company focused on developing novel cancer medicines. It expects Seagen's products to yield $3.1 billion in revenue this year and $10 billion in annual revenues by 2030.Still, its share price has fallen more than 50% since reaching an all-time high in December 2021.Starboard's targets cut across industries, including 23 campaigns in the healthcare sector, according to 13D Monitor. Besides Bristol-Myers Squibb, other prior targets include CVS and medical records and technology company Cerner.Pfizer did not respond to a request for comment. <h4 id="cbcdd8ad-013b-426e-8431-6c2b54c6859d">Greatest hits</h4><ul><li>2012: Starboard is credited with spurring AOL CEO Tim Armstrong to sell assets, including the sale of 800 patents to Microsoft for $1.1 billion.</li><li>2013: Starboard secured three seats on the board of Office Depot, which later agreed to merge with Staples before the Federal Trade Commission blocked the merger, citing antitrust reasons.</li><li>2014: Starboard replaced the entire board of Darden Restaurants, owner of Olive Garden. By 2015, Starboard was widely credited with turning Darden Restaurants around in part by rethinking how Olive Garden served its iconic breadsticks.</li><li>2019: Jeff Smith is named chairman of the board of pizza chain Papa John's. He immediately expanded the board by bringing in two new independent directors.</li><li>2022: Starboard urged software giant Salesforce to cut costs and improve its margins. The stock has nearly doubled since Starboard acquired a stake.</li><li>2024: After facing pressure from Elliott Management and Starboard, Starbucks replaced its CEO.</li></ul>

Meet Jeff Smith, the hedge-fund investor taking on Pfizer

<ul class="summary-list"><li>President Joe Biden tested positive for COVID-19, the White House said.</li><li>Biden was set to speak at the UnidosUS conference in Las Vegas on Wednesday.</li></ul><a target="_blank" class="" href="https://www.businessinsider.com/biden-virtual-roll-vote-explainer-democratic-nomination-drop-out-election-2024-7">President Joe Biden</a> tested positive for COVID-19 on Wednesday, according to the White House."Earlier today following his first event in Las Vegas, President Biden tested positive for COVID-19. He is vaccinated and boosted and he is experiencing mild symptoms. He will be returning to Delaware where he will self-isolate and will continue to carry out all of his duties fully during that time," Press Secretary Karine Jean-Pierre said in a statement provided to Business Insider. "The White House will provide regular updates on the President's status as he continues to carry out the full duties of the office while in isolation."The White House also provided a note from Biden's doctor that said the president tested after having a runny nose, cough, and general malaise. The note said Biden was experiencing mild symptoms and that his respiratory rate, temperature, and blood oxygen levels were normal. It also said he had received a first dose of Paxlovid.Biden, 81, has been in Nevada since Monday night and was set to speak at a conference for UnidosUS in Las Vegas on Wednesday.Janet Murguía, CEO of UnidosUS, told conference attendees that Biden tested positive for COVID-19 after the president was an hour and a half late to his planned speaking event, according to <a target="_blank" class="" href="https://www.cnn.com/2024/07/17/politics/joe-biden-tests-positive-covid-19/index.html">CNN</a>."I was just on the phone with President Biden. And he shared his deep disappointment at not being able to join us this afternoon. The president has been at many events, as we all know, and he just tested positive for COVID," Murguía said at the conference.Biden departed Nevada, a key battleground state for the election in November, on Air Force One on Wednesday, telling reporters at the scene, "I feel good," according to the <a target="_blank" class="" href="https://apnews.com/article/biden-covid-las-vegas-ff29bb071f18b993d20dedccbe2c8fbf">Associated Press</a>.

Biden tests positive for COVID-19

<ul class="summary-list"><li>The general public's attitude toward COVID is more relaxed than ever, even amid a summer surge.</li><li>Doctors say relaxed COVID precautions are to be expected and are not necessarily a bad thing.</li></ul>Gone are the days of scrubbing surfaces, sudden <a target="_blank" class="" href="https://www.businessinsider.com/covid-shut-down-school-two-days-after-classes-started-2022-1">school closures</a>, and social distancing.Where a positive COVID-19 test once wrought panicked <a target="_blank" class="" href="https://www.businessinsider.com/covid-19-mistakes-us-focus-on-contact-tracing-not-sequencing-2021-3">contract tracing </a>and guaranteed two weeks of isolation, these days, a diagnosis sparks relatively little worry for most people.Even amid a summer spike in cases — everyone from President <a target="_blank" class="" href="https://www.businessinsider.com/biden-tests-positive-for-covid-19-2024-7#:~:text=President%20Joe%20Biden%20tested%20positive,Press%20Secretary%20Karine%20Jean%2DPierre.">Joe Biden</a> to the 2024 Summer Olympians seems to be battling the virus — the general public's attitude toward the pandemic that upended our lives more than four years ago is more relaxed than ever.The federal public health emergency for COVID expired in May 2023, officially <a target="_blank" class="" href="https://www.businessinsider.com/the-covid-19-global-health-emergency-is-over-who-says-2023-5">ending the crisis</a>, at least in name, more than three years after it was first declared. Since then, thanks to high infection and immunization rates, the country has continued climbing toward the herd immunity doctors so desperately sought in the early days of the pandemic, four medical professionals told Business Insider."The risk perception and anxiety around acute COVID infection has definitely lessened," said Dr. Anita Chopra, an internist at the University of Washington medical system. "People are interacting and mingling more like in pre-pandemic times."Healthcare professionals told BI that the public's more relaxed attitude toward COVID is ultimately a good thing. <a target="_blank" class="" href="https://www.businessinsider.com/life-returning-to-normal-labor-market-vaccines-pandemic-2021-11">A return to normality</a> was the goal, after all.But COVID is still very present and very much a potential threat, especially for the immunocompromised and those unlucky enough to <a target="_blank" class="" href="https://www.businessinsider.com/who-official-individuals-coronavirus-infection-unlucky-long-covid-2022-6">develop long COVID symptoms</a> — up to 10% of patients, according to some doctor estimates. Meanwhile, relaxed masking and declining vaccination rates, while to be expected at this point, could be linked to the rising case numbers doctors are seeing in clinics around the country, medical professionals told BI."We need to acknowledge that we're in a very different place now than we were at the height of the pandemic," said Dr. Eric Chow, chief of communicable disease epidemiology and immunizations at Public Health Seattle and King County. "But so long as COVID-19 continues to circulate, there are health implications to getting infected."<h2 id="8540c815-ae27-4465-8106-21a572b3f035">Evolving behaviors and beliefs</h2>Many of the early-day pandemic precautions have all but disappeared in 2024. Chief among them, according to doctors, are <a target="_blank" class="" href="https://www.businessinsider.com/mask-mandates-lifted-states-reasonable-experts-2022-2">masking</a>, isolations, and vaccinations.Soon after the pandemic emerged, medical professionals emphasized masking as a key way to slow the spread of the virus.The face coverings quickly became a contentious cultural topic and among the <a target="_blank" class="" href="https://www.businessinsider.com/trumps-decision-to-oppose-masks-bizarre-self-sabotaging-coronavirus-pandemic-2020-6">most politicized aspects</a> of COVID. But these days, even many who once championed masks have ditched the deterrent entirely. An August 2023 Yahoo News/YouGov <a target="_blank" class="" href="https://www.yahoo.com/lifestyle/only-12-percent-of-americans-wear-mask-in-public-194019882.html">poll</a> of 1,665 US adults found that 12% of respondents said they were masking — down from 60% in January 2022. And doctors told BI that they've seen a steady decrease in masking since then."I think the public has appropriately adjusted their attitudes to what they hear in the news and what they see around them," said Dr. Edward Jones-Lopez, infectious disease specialist with Keck Medicine at the University of Southern California.More worrying to medical professionals is the <a target="_blank" class="" href="https://www.businessinsider.com/covid-vaccine-us-vaccination-sites-joe-biden-2021-4">decline in vaccinations.</a>While early immunization rates helped bolster immunity, vaccination uptake has been on the decline in recent years, and fewer and fewer people are keeping up to date with their booster shots, a preventive step the <a target="_blank" class="" href="https://www.cdc.gov/covid/vaccines/stay-up-to-date.html#:~:text=Everyone%20aged%205%20years%20and,of%20updated%20COVID%2D19%20vaccine.">CDC recommends</a> in its COVID guidelines.Most medical professionals also recommend a yearly COVID-19 vaccine. There's a new shot coming out in September. But Chow, who previously worked at the Centers for Disease Control and Prevention at the height of the pandemic, said most people aren't aware of the recommended vaccine schedule — a challenge that is indicative of a larger problem doctors are trying to navigate in this new COVID age."People are much more fatigued by COVID messaging," he said. "We're trying to right-size the appropriate message to make sure people continue to acknowledge the health impacts of COVID."<h2 id="3c719499-920d-46e7-b315-35ec4a1cdc50">The long COVID scare</h2>Relaxed attitudes are not necessarily a bad thing, according to doctors."I think it's to be expected as we learn more about the virus over these four years and as we've developed these other COVID countermeasures to address infection," said Dr. Jessica Bender, a primary care doctor at Harbor View Medical in Seattle and the co-director at the university's long COVID clinic.On the one hand, people are generally not getting as sick as they once did when ill with COVID, medical professionals told BI. On the other hand, this summer seems to have brought yet another COVID surge with a spike in cases.People don't typically equate respiratory illnesses with the warmer months, but an increase in summer socializing combined with the general decrease in preventive measures is likely fueling the uptick, Bender said.For an unlucky subset of patients, a COVID diagnosis — even in this new relaxed era — could mean <a target="_blank" class="" href="https://www.businessinsider.com/long-covid-survivor-its-wrecked-my-life-2022-1">long-term challenges.</a>Doctors define long COVID as any infection related to the virus that is present for at least three months, said Chopra, who treats patients at the UW long COVID clinic. The often <a target="_blank" class="" href="https://www.businessinsider.com/healthcare-workers-nurses-long-covid-impact-careers-labor-shortage-2022-5">debilitating</a> condition is indiscriminate in who it affects. Up to 10% of all people who get COVID are susceptible, according to Chopra, and patients of all ages, genders, races, and vaccination statuses can present with long COVID.<div type="image" title="A young girl gets a COVID vaccine" height="2661" width="4000" msid="112065018" hostid="261" sizebytes="341938"></div>Even as the country relaxes its COVID response, doctors said they are still seeing many new patients presenting with long COVID each day. The condition has at least <a target="_blank" class="" href="https://www.businessinsider.com/common-long-covid-symptoms-hair-loss-vertigo-low-libido-2022-7">200 known signs and symptoms</a> that range from shortness of breath to chronic fatigue and brain fog.Doctors told BI they'd treated several patients who have been forced to <a target="_blank" class="" href="https://www.businessinsider.com/long-covid-symptoms-disability-insurance-unemployment-quit-job-2022-11">stop working</a> or rendered unable to participate in any physical activity because of a long COVID diagnosis. A 2023 <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721155/">study</a> published in the National Library of Medicine explored a possible link between long COVID and the risk of suicide because of the condition's tendency to inflict depression, anxiety, posttraumatic symptoms, sleep disturbances, fatigue, and cognitive deficits.Medical professionals are doing their best to understand long COVID, but admit that there's still much to learn. According to the CDC, about 17 million people <a target="_blank" class="" href="https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm">reported</a> having long-term COVID-19 in March 2024.For these people, the pandemic is still very real."When I treat people with long COVID, they are always masked," Chopra said.<h2 id="c71342ed-0973-4d09-978b-dae3bd11fc3e">The future of COVID</h2>As doctors look to the <a target="_blank" class="" href="https://www.businessinsider.com/red-cross-says-world-is-dangerously-unprepared-for-next-pandemic-2023-1">future</a> of COVID, little is for sure."We always say the one thing that is predictable about COVID is its unpredictability," Chow said.But medical professionals told BI they are optimistic that even as the virus continues to evolve, the next few years will continue to look like the past year, with small seasonal surges and hopefully less intense illness.While lax attitudes may be a welcome sign of a cautious new normal, doctors said it's important to remember the lessons we've collectively learned from COVID. The precautions that proved useful against the virus protect people from other illnesses, too.Just because the world has adapted to COVID-19, medical professionals say, doesn't mean we should drop the hygiene, <a target="_blank" class="" href="https://www.businessinsider.com/air-circulation-coronavirus-how-to-judge-ventilation-systems-2020-8">ventilation</a>, and masking lessons learned along the way."We've learned so much about how we can protect ourselves," Chow said. "It's hard to see people leave some of those precautions behind."Doctors recommend people gauge their individual risk, as well as the risk of those close to them when considering which precautions to take in this new COVID age. Most medical professionals still recommend masking, testing, and visiting a doctor after testing positive."We're aiming to get to a state where COVID is not a threat to our healthcare system," Bender said. "And not a threat to our lives and livelihoods.

Most people don't really care about COVID anymore. That's good — and bad. 

<ul class="summary-list"><li>Starboard Value has taken a significant stake in Pfizer, said people familiar with the matter.</li><li>The drug giant's stock has dropped significantly since its 2021 COVID-19 vaccine rollout.</li></ul>Starboard Value has its next target: pharma giant Pfizer.The activist investor has informed Pfizer that it has taken a significant stake in the drugmaker, people familiar with the matter told Business Insider.Pfizer stock has fallen sharply since it reached record highs in 2021 during the rollout of its COVID-19 vaccine.The Wall Street Journal <a target="_blank" class="" href="https://www.wsj.com/health/pharma/activist-starboard-value-takes-1-billion-stake-in-pfizer-89591cb6">earlier reported the Starboard stake</a>.Starboard, which managed $8.5 billion in assets at the start of the year, has recently taken stakes in coffee chain Starbucks and Match Group, the owner of dating app Tinder. It also has a stake in Rupert Murdoch's News Corp and has pushed for a breakup of the media conglomerate.

Activist investor Starboard has just informed Pfizer it has taken a significant stake 

<ul class="summary-list"><li>Vaccine stocks have tumbled since Trump appointed vaccine skeptic Robert F. Kennedy Jr. to health secretary.</li><li>Vaccine-makers Moderna, Pfizer, and GSK saw sharp losses.</li></ul>It's been a tough day for health stocks since Donald Trump announced his appointment of <a target="_blank" href="https://www.businessinsider.com/trump-robert-f-kennedy-jr-rfk-department-health-human-services-2024-11">Robert F. Kennedy Jr.</a> — a staunch vaccine skeptic — as health secretary.The news, which came late in the day on Thursday, sent the shares of vaccine-makers sharply lower on Friday, with <a target="_blank" class="" href="https://markets.businessinsider.com/stocks/mrna-stock">Moderna</a> leading the losses, falling as much as 10%. <a target="_blank" class="" href="https://markets.businessinsider.com/stocks/pfe-stock">Pfizer</a> and <a target="_blank" class="" href="https://markets.businessinsider.com/stocks/nvax-stock">Novavax</a> both dropped 6% at intraday lows, while <a target="_blank" class="" href="https://markets.businessinsider.com/stocks/gsk-stock">GSK</a> lost 5%.But the selling wasn't contained to just vaccine names. It spread into US-exposed European healthcare stocks, such as Novo Nordisk and Roche, which were down 5% and 3% at intraday lows, respectively.The losses extend a days-long skid for the sector after the election results last week saw investors boost bets that Kennedy — a key Trump ally — would notch a cabinet role.Since Election Day, Moderna has fallen more than 30%, while Pfizer has slid 11%. Those losses have stood in contrast to the rally enjoyed by the rest of the market, which has <a target="_blank" class="" href="https://markets.businessinsider.com/news/stocks/trump-election-win-stock-market-today-record-high-sp500-dow-2024-11">rallied</a> on the hopes that Trump's lighter regulatory stance and corporate tax cuts could boost corporate earnings.<a target="_blank" href="https://www.businessinsider.com/robert-f-kennedy-jr-views-vaccines-autism-testing-debunked-2023-7">Kennedy</a> has long railed against vaccines, once calling those that protect against Covid-19 a "crime against humanity." He has treaded more carefully in recent weeks, though, and has said he wouldn't outright ban vaccines."If vaccines are working for somebody, I'm not going to take that away. People ought to have choice," he told <a target="_blank" href="https://www.nbcnews.com/politics/2024-election/trump-win-rfk-jr-says-wont-take-away-anybodys-vaccines-rcna178955">NBC</a> after Trump's election.Since Trump's election win, several analysts have downgraded their outlooks on vaccine stocks amid the rising uncertainty in the industry. Bank of America analysts lowered their price target on Moderna last week, from $110 to $90, partially citing uncertainty after Trump's election win, while Deutsche Bank analyst Emmanuel Papadakis cut his rating on GSK to a hold after Kennedy's appointment."We consider vaccines to be amongst the greatest scientific achievements to impact public health: unfortunately this view is not shared by the nominee," Papadakis wrote in a client note <a target="_blank" class="" href="https://www.bloomberg.com/news/articles/2024-11-15/health-stocks-slide-as-trump-picks-vaccine-skeptic-kennedy">seen by Bloomberg</a>.Formerly an environmental justice lawyer, Kennedy pivoted to running an anti-vaccine charity in recent years, and ran for president as an independent candidate in this election cycle. He dropped out to <a target="_blank" href="https://www.businessinsider.com/rfk-jr-drops-out-presidential-race-2024-8">endorse Trump</a> in August, which some sources reported was a bid to <a target="_blank" href="https://www.businessinsider.com/rfk-wanted-white-house-job-exchange-for-endorsing-trump-report-2024-7">secure a position</a> in the administration.In his role as <a target="_blank" href="https://www.businessinsider.com/how-rfk-jr-plans-to-make-america-healthy-again-2024-11">health secretary</a>, Kennedy will have a top role in health policy in the US, but likely won't be able to actually control which vaccines children are required to get for school. That will remain up to individual states, but he could change vaccine requirements for federal employees or the US military.That's if the Senate confirms his appointment, which some have said could be a close vote considering mixed reactions among policymakers so far.Kennedy has also promoted removing fluoride from water supplies and overhauling federal food regulations, and has supported products like raw milk, which the Food and Drug Administration warns against.He's also floated hopes to cut highly processed food from school lunches, which was a priority under the Obama administration.

Health stocks are tumbling after Trump's appointment of vaccine skeptic RFK Jr.

When Josef Woodman's shoulder gave out in 2012 — strained from chopping firewood on his farm outside Chapel Hill, North Carolina — he said he was quoted between $2,400 and $3,200 for an MRI at Duke University Hospital.He didn't want to shell out the cost of a nice vacation just to find out he didn't need surgery, so he decided to wait, even as his mobility decreased to the point where he had to severely limit his farm work and could hold only one-third of the weight he normally could. Two years later, his patience was rewarded: While on a work trip to Bangkok, he got an MRI for just $460, landing an appointment two days after his consultation at a hospital."The results came back and they said, 'You don't need surgery. You've got a separated rotator cuff,'" Woodman said. The surgeon prescribed physical therapy, which he completed in the US. "The shoulder got way better," he told me. He was glad he waited.Like Woodman, millions of Americans travel abroad for medical procedures each year, saving anywhere from 40% to 90% on the services they receive. Many <a target="_blank" href="https://www.amjmed.com/article/S0002-9343(18)30620-X/fulltext">don't have health insurance</a> or don't get coverage for the procedures they seek out — dental work and cosmetic procedures like breast implants and liposuction are by far the most popular. There's also a small but growing market for people seeking thorough checkups and testing abroad. An ascendant medical-tourism industry is offering these types of screenings, including MRIs and electrocardiograms, in beautiful locations around the world and packaging them with transportation, accommodations, food, shopping, and sightseeing. And with an increasing obsession with "wellness" and celebrities like Kim Kardashian promoting full-body imaging, it's easy to see why more and more Americans are looking to pair cabanas with CAT scans."If you've got some kind of joint pain, or if you have some kind of condition that isn't progressing, incorporate that into your normal travel plans," Woodman, now 72, said. In 2007, he founded Patients Beyond Borders, a healthcare-consulting company that helps Americans plan medical vacations, after growing up taking trips to Mexico for dental work with his dad. "In any kind of industrialized nation, you'd be able to get access to good-quality screening and people who can interpret the results," he said.Medical tourism comes with risks; the American Medical Association recommends going only to medical facilities recognized by international accrediting bodies and following up testing with care at home. But a growing number of Americans are willing to take those risks, as suites of tests abroad are often cheaper and faster than just a single test in the US."We just don't have a preventative-oriented society here in the United States," Woodman said. "Our approach is reactive."In a July <a target="_blank" href="https://www.tiktok.com/@bryn.elise/video/7386406512593325355?lang=en">TikTok</a> that's amassed over 17 million views, Bryn Elise documented her experience at a Turkish hospital where she received over 30 scans and tests, including an EKG, chest X-ray, and abdominal and thyroid ultrasounds, in a single day. The bill? $830. Without insurance, the cost of an EKG alone in the US <a target="_blank" href="https://enhancehealth.com/blog/how-much-does-an-ekg-cost-at-urgent-care-without-insurance/#:~:text=The%20total%20cost%20of%20an,where%20you%20get%20the%20service.">can vary from $100 to $5,000</a>."Personally, I'd rather spend $700 on a flight to Turkey, get dozens of tests there, and take a whole vacation than spend the thousands that this would have cost in the United States," Elise said in the video, which also featured clips of her on a beach, poolside, and eating a spread of delicious-looking Turkish veggie bowls. The 29-year-old health- and beauty-tourism influencer said she booked the trip because she wanted to investigate some "mysterious ailments," including brain fog, vision problems, and heart palpitations, without paying America's sky-high healthcare costs. She told her followers she had struggled with an eating disorder for 10 years and that "since our US checkups are only a tap on the knee and a blood-pressure check, I've been low-key terrified that I've caused permanent damage to my body but would never find out until it's too late."Her tests unearthed an astigmatism, early signs of osteoporosis, and "critically low" levels of vitamin B12. "The feeling of impending doom I've had due to health concerns is gone," Elise said.She chose a hospital that had been accredited by the Joint Commission International, an Illinois-based organization that has accredited over 1,000 health facilities in more than 70 countries. Dr. Paulo Neno, an international-accreditation surveyor at the commission, told Business Insider the accreditation process takes up to two years to complete and is renewed every three years. It includes a 12-part evaluation, during which a team of doctors and nurses visit the medical facility and assess everything from its operating theaters and intensive-care units to its power and water systems."We are focused on understanding how they are providing safe care for high-risk patients," Neno said.It's unclear, though, how many medical tourists visit accredited facilities, and there's still the question of whether all these tests are useful for someone who is seemingly in good health. Woodman knew he had an issue that needed to be examined, but Elise was more interested in a holistic screening regimen. One person commented on Elise's TikTok, "The hypochondriac in me thinks this is the perfect vacation. I'd go every year."Since COVID-19 came into the picture, health screenings and extensive physicals have received some buzz. Last year, Kardashian got a full-body MRI done by Prenuvo, a US chain of diagnostic clinics that offers the service for $2,500. In an Instagram post promoting it, Kardashian described it as a "life saving machine" that could detect cancer or conditions like aneurysms in their earliest stages. Especially given the <a target="_blank" href="https://www.businessinsider.com/colon-cancer-cases-doubled-young-people-2024-5">rise in colon cancer</a> among young people — a disease that can spread with no or minimal symptoms — <a target="_blank" href="https://www.businessinsider.com/get-colonoscopy-colon-cancer-symptoms-colorectal-oncologist-2024-4">early screenings</a> are on more people's minds.But Arturo Vargas Bustamante, an associate professor of health policy and management at the University of California, Los Angeles, said these kinds of rigorous tests can often do more harm than good."You may get a lot of things that you may not need based on your age profile, or you may get screenings that ultimately would find something that could lead to treatment that may harm you," he said. US guidelines on which demographics should get tested are based on scientific evidence, he added, while clinics abroad may be more motivated by profit.If a test finds cancer at a very early stage when it's very slow-moving, Vargas Bustamante said, the patient may feel compelled to treat it immediately, subjecting themself to chemotherapy and radiation. But in reality, it's possible they could have gone years without needing to start treatment. "Sometimes knowing too much may not be that good for you," he said.Others, however, think that America's lack of access to robust preventive screening is a critical failure.Dr. Misael Uribe Ramos is the director of international medicine at Médica Sur in Mexico City, a Joint Commission International-accredited hospital that offers checkups with eight different specialists for $1,600. Uribe Ramos has seen interest in rigorous physicals boom since the outbreak of the COVID-19 pandemic — and he thinks it's a good thing.Often when you go to the doctor, it's to treat a specific issue or disease, he said. "But why is that? Because you don't have prevention," he said. "Prevention is the best way to be healthy."In America, chronic illnesses such as heart disease, diabetes, and cancer are leading causes of death and disability, driving the majority of the US's $4.5 trillion in yearly healthcare expenses, <a target="_blank" href="https://www.cdc.gov/chronic-disease/about/index.html">according to</a> the Centers for Disease Control and Prevention. These illnesses are largely preventable. The CDC also says that between 30% and 50% of cancers diagnosed today could be prevented by reducing risk factors (like not smoking and maintaining a healthy body weight) and getting recommended screenings and vaccinations. However, according to the <a target="_blank" href="https://health.gov/news/202401/prevention-still-best-medicine">US Office of Disease Prevention and Health Promotion</a>, only 5.3% of Americans 35 and older received all recommended clinical prevention services in 2020 — a number that dropped from 8.5% in 2015. Why? Simply put, many Americans aren't regular healthcare users. They often don't have a family doctor, they live too far from one, they don't have a way to get there, or they simply can't afford it, the Office of Disease Prevention and Health Promotion says. Meanwhile, preventive-care services aren't prioritized because healthcare providers are paid to treat diseases — not to prevent them by keeping people healthy. A 2020 study said the National Academy of Medicine <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309216/">estimated</a> that missed prevention opportunities cost the US $55 billion annually.Other countries take a different approach. In Japan, for instance, the most basic annual checkups include EKGs, chest X-rays, blood tests, eye and hearing tests, and stool and urine tests. And some residents require a more comprehensive version that includes cancer screening. Japanese employers are required to provide them for all of their employees. In 2019, about 74% of men and 66% of women in Japan completed some type of medical checkup, according to the country's Ministry of Health, Labour and Welfare.South Korea's regimen is similar to Japan's. On a work trip there in 2010, Woodman had extensive testing done, including an MRI and CT scan, as part of a "wellness preventative program" he tried out for work, he said. He was offered an endoscopy and colonoscopy as part of the package but declined."Testing in the United States is really kind of pathetic," Woodman said. "They weigh you. They take your blood test. 'How tall are you?' And that's pretty much it."Americans seeking better preventive screening tend to visit South Korea, Thailand, and the United Arab Emirates, while Mexico, Barbados, and Thailand are popular for genetic and fertility testing, as well as testing related to gender-affirming care, medical-tourism advocates told BI.Many of these countries have hospitals that cater to foreigners. In Mexico, Médica Sur's checkups take about five hours, with screenings across disciplines such as internal medicine, cardiology, gynecology, and ophthalmology. (In the US, a typical physical takes less than an hour.) Packages include breakfast, transportation, accommodation, menus catering to dietary restrictions, discounted sightseeing for an extra cost, and concierge staff who help patients coordinate their stay and remain by their side for the duration. The hospital is also connected to a Holiday Inn if visitors want to stay on-site.Results are available within two weeks, at which point the patient can discuss the findings with a doctor in person or remotely; a checkup three months later is also included in the price. If, for example, the screenings indicate a malignant tumor, Uribe Ramos said, doctors will explain to a patient which follow-up tests they need, either in their home country or at Médica Sur. He recommends getting a thorough exam once a year.Since opening its international-medicine wing in 2019, the hospital has seen 5,000 foreign patients, most of them American and Canadian, Uribe Ramos said.Imani Bashir was living in Cancún three years ago when she felt what she thought was a lump in her breast. At the time she was 34 — <a target="_blank" href="https://www.cancer.org/cancer/screening/screening-recommendations-by-age.html#:~:text=Women%20ages%2040%20to%2044,should%20get%20mammograms%20every%20year.">young</a> to be receiving a mammogram — but her family had a history of the disease, so she booked an appointment anyway. In the US, the median <a target="_blank" href="https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e18917">cost</a> of a mammogram ranges from $140 to $360 for women who aren't insured. In Mexico, it was under $50. As a Black woman who grew up in the US without health insurance, the 37-year-old communications director found the experience especially validating."When we go to the doctor and say that we're in pain, it's kind of just shooed away, like it's not a big deal," Bashir said. In Mexico, the medical center didn't question her. Now that she's living in Washington, DC, she continues to travel to Mexico for both her and her son's dental appointments and other medical issues because it's cheaper and easier to get appointments. "It always feels good when you feel like you can take care of yourself, and financially, it's not going to be a detriment to your life and your health," she says.Given how many people experience difficulty navigating the American healthcare system, it's no surprise that the medical-tourism market is growing rapidly. Patients Beyond Borders estimates the industry is growing between 15% and 25% each year. And 2022 <a target="_blank" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104082/#:~:text=The%20increase%20in%20medical%20tourism,other%20time%20in%20the%20past.">research</a> found that the increase in international tourism had helped fuel the trend. As <a target="_blank" href="https://www.businessinsider.com/travel-agents-back-gen-z-millennials-vacation-planning-overseas-resorts-2024-6">more people spend time abroad</a>, it becomes easier to tack a few small medical tests onto your trip.Vargas Bustamante thinks traveling internationally for rigorous testing probably most benefits healthy people who just want "peace of mind." Despite the risk factors, the industry's growing appeal illustrates the limitations of American healthcare."Why would someone have to buy a plane ticket to go all the way on the other side of the world just for an adequate amount of healthcare? It's nuts," Bashir said. "But if people have the privilege, if people have the money to be able to do so, then I say, yeah."<a target="_blank" class="" href="https://www.businessinsider.com/author/manisha-krishnan">Manisha Krishnan</a> is an Emmy award-winning journalist who covers healthcare. She is based in Brooklyn.

You Searched For "Pfizer Covid 19 Vaccine" and got 11 results

Pan-India rollout of U-WIN to track routine immunisations likely by Aug end

PTI

AstraZeneca withdraws COVID-19 vaccine worldwide, cites commercial reasons

ANI

BHU study on Covaxin side effects poorly designed, critically flawed: ICMR Director General

PTI

TTS: Clot in blood vessels occurs in rare cases with certain vaccines, says medical expert amid reports over AstraZeneca

ANI

Singapore seeing new COVID-19 wave, minister advises wearing of masks

PTI

Meet Jeff Smith, the hedge-fund investor taking on Pfizer

Alex Morrell

Biden tests positive for COVID-19

Kelsey Vlamis,Brent D. Griffi…

Most people don't really care about COVID anymore. That's good — and bad.

Erin Snodgrass

Activist investor Starboard has just informed Pfizer it has taken a significant stake

Alex Morrell

Health stocks are tumbling after Trump's appointment of vaccine skeptic RFK Jr.

Kelly Cloonan

Mojitos and an MRI: Meet the Americans who are getting health screenings on vacation

Manisha Krishnan

Popular Keywords

Buying Guides